Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

NCT05669807 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

184

Enrollment

OTHER

Sponsor class

Conditions

Second Line Treatment of Gastric Cancer

Interventions

DRUG: Camrelizumab
DRUG: Albumin-Bound Paclitaxel
DRUG: Irinotecan

Sponsor

Zhejiang Cancer Hospital